Stuart Grant Biography and Net Worth

Major Shareholder of Hyperion DeFi

Stuart Grant is the Major Shareholder of Hyperion DeFi.

What is Stuart M. Grant's net worth?: The estimated net worth of Stuart M. Grant is at least $541.61 thousand as of July 2nd, 2024. Grant owns 136,426 shares of Hyperion DeFi stock worth more than $541,611 as of December 4th. This net worth approximation does not reflect any other investments that Grant may own. Learn More about Stuart M. Grant's net worth.
How do I contact Stuart M. Grant?: The corporate mailing address for Grant and other Hyperion DeFi executives is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. Hyperion DeFi can also be reached via phone at (917) 289-1117 and via email at [email protected]. Learn More on Stuart M. Grant's contact information.
Has Stuart M. Grant been buying or selling shares of Hyperion DeFi?: Stuart M. Grant has not been actively trading shares of Hyperion DeFi in the last ninety days. Most recently, on Tuesday, July 2nd, Stuart M. Grant bought 18,939 shares of Hyperion DeFi stock. The stock was acquired at an average cost of $52.80 per share, with a total value of $999,979.20. Following the completion of the transaction, the insider now directly owns 136,426 shares of the company's stock, valued at $7,203,292.80. Learn More on Stuart M. Grant's trading history.
Who are Hyperion DeFi's active insiders?: Hyperion DeFi's insider roster includes Stuart Grant (Major Shareholder), Tsontcho Ianchulev (CEO), Kenneth Lee, Jr. (Director), Charles Mather, IV (Director), and Michael Rowe (COO). Learn More on Hyperion DeFi's active insiders.

Stuart M. Grant Insider Trading History at Hyperion DeFi

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/2/2024	Buy	18,939	$52.80	$999,979.20	136,426
3/28/2024	Buy	1,250	$78.40	$98,000.00	67,883
3/19/2024	Buy	625	$98.40	$61,500.00	66,633
3/8/2024	Buy	133	$126.40	$16,811.20	66,008
8/16/2023	Buy	562	$152.80	$85,873.60	65,499
5/25/2023	Buy	1,103	$212.00	$233,836.00	64,937
6/21/2022	Buy	1,250	$132.00	$165,000.00	63,562
5/10/2022	Buy	625	$158.40	$99,000.00	61,999
5/4/2022	Buy	300	$180.80	$54,240.00	61,374
4/21/2022	Buy	485	$207.20	$100,492.00	60,824
2/22/2022	Buy	525	$220.00	$115,500.00
2/18/2022	Buy	125	$228.00	$28,500.00
2/7/2022	Buy	450	$237.60	$106,920.00
12/15/2021	Buy	1,250	$276.00	$345,000.00
11/15/2021	Buy	937	$291.20	$272,854.40
10/29/2021	Buy	193	$300.00	$57,900.00
10/25/2021	Buy	422	$320.00	$135,040.00
8/19/2021	Buy	625	$318.40	$199,000.00
8/17/2021	Buy	292	$320.00	$93,440.00
4/19/2021	Buy	383	$391.20	$149,829.60	53,496
3/5/2021	Buy	437	$440.00	$192,280.00	53,184
10/12/2020	Buy	1,250	$284.00	$355,000.00	52,121
9/24/2020	Buy	937	$239.20	$224,130.40	50,871
8/19/2020	Buy	4,162	$288.00	$1,198,656.00	44,914
3/23/2020	Buy	11,290	$164.80	$1,860,592.00
11/12/2019	Buy	374	$216.00	$80,784.00	27,827
10/30/2019	Buy	312	$228.00	$71,136.00	27,827
10/16/2019	Buy	187	$251.20	$46,974.40	27,827
10/14/2019	Buy	83	$260.00	$21,580.00	27,827
10/2/2019	Buy	62	$266.40	$16,516.80	27,827
9/30/2019	Buy	224	$296.00	$66,304.00	27,827
9/27/2019	Buy	3	$320.00	$960.00	27,827

Stuart M. Grant Buying and Selling Activity at Hyperion DeFi

Hyperion DeFi Company Overview

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Today's Range

Now: $3.97

$3.50

$4.09

50 Day Range

MA: $6.70

$3.61

$11.83

2 Week Range

Now: $3.97

$0.85

$17.99

Volume

408,169 shs

Average Volume

328,192 shs

Market Capitalization

$32.16 million

P/E Ratio

N/A

Dividend Yield